<DOC>
	<DOC>NCT01471197</DOC>
	<brief_summary>The purpose of this trial is to determine whether Ipilimumab will prolong survival when compared to Pemetrexed in subjects with nonsquamous, non-small cell lung cancer.</brief_summary>
	<brief_title>Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>For additional information, please contact the BMS oncology clinical trial information service at 8552160126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation. NonSquamous, NonSmall Cell Lung Cancer Recurrent/Stage IV Nonsmall cell lung cancer (NSCLC) Eastern Cooperative Oncology Group (ECOG) 0 or 1 Not progressing after 4 cycles of a platinumbased first line chemotherapy Brain Metastases (unless stable) Autoimmune Diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>